What Next TBD: The Rise of Off-Brand Ozempic
Slate News
00:00
The Telehealth Boom and GLP-1 Medications
This chapter examines the surge of telehealth companies like HIMS and Row in the sale of GLP-1 medications, contrasting their practices with potential black market alternatives. It also delves into the implications of easy online prescriptions, the risks of insufficient medical oversight, and the heightened scrutiny on compounding pharmacies amidst rising medication concerns.
Transcript
Play full episode
